A groundbreaking study published in the September 27th issue of JAMA Neurology reveals that an accessible and cost-effective anti-seizure medication can substantially improve learning, memory, and other cognitive functions in individuals with Alzheimer’s disease who exhibit underlying epileptic activity in their brains. This discovery opens a promising new avenue for managing cognitive decline in a significant subset of Alzheimer’s patients, potentially shifting diagnostic and treatment paradigms.
Unveiling the "Epileptic Variant" of Alzheimer’s
The research, led by Dr. Keith Vossel, Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, focused on a phenomenon often overlooked in the diagnosis of Alzheimer’s disease: "silent epileptic activity." This refers to seizure-like electrical disturbances in the brain that occur without the characteristic physical convulsions, making them undetectable through standard clinical observation.
"This is a drug that’s used for epilepsy," Dr. Vossel explained in an interview. "We used it in this study for Alzheimer’s patients who had evidence of silent epileptic activity, which is seizure-like brain activity without the associated physical convulsions."
Alzheimer’s disease (AD), the most prevalent cause of dementia globally, is characterized by progressive memory loss, difficulties with problem-solving, word retrieval, and spatial navigation. While seizures are observed in an estimated 10-22% of Alzheimer’s patients, a much larger proportion, between 22-54%, exhibits this "silent" epileptic activity. Dr. Vossel’s prior research had already established a correlation between the presence of silent epileptic activity and a more accelerated decline in cognitive function among Alzheimer’s patients.
The Choice of Levetiracetam: A Cost-Effective Solution
The researchers selected levetiracetam, an anti-seizure medication approved by the U.S. Food and Drug Administration (FDA) in 1999. This drug had previously demonstrated efficacy in animal models of Alzheimer’s disease, making it a logical candidate for human trials. Crucially, levetiracetam is now available as a generic medication, with an estimated annual cost of around $70. The dosage employed in this study was a modest 125 mg twice daily, significantly lower than typical doses used for epilepsy management, suggesting a potential for broader tolerability and reduced side effects.
Rigorous Screening and Innovative Methodology
The study enrolled 54 participants diagnosed with mild Alzheimer’s symptoms. A critical initial step involved screening for silent epileptic activity using a combination of electroencephalogram (EEG) and magnetoencephalogram (MEG) over an extended monitoring period. The overnight EEG provided a broad overview of brain electrical activity, while the hour-long MEG, which records magnetic fields generated by neuronal currents, offered enhanced sensitivity for detecting subtle epileptic activity that might be missed by EEG alone.
"MEG can pick up epileptic activity that EEGs miss because it’s looking at a different population of brain cells," Dr. Vossel elaborated.
Following the screening, 34 participants were deemed eligible for the trial. Nearly 40% of these individuals were found to have detectable epileptic activity. Patients with pre-existing seizure disorders and those already on anti-seizure medications were excluded to ensure the study’s focus remained on the effects of levetiracetam on Alzheimer’s-related cognitive changes.
The trial employed a sophisticated crossover design to maximize the data obtained from each participant while minimizing bias. Participants were divided into two groups. One group initially received a placebo for four weeks, followed by a four-week washout period with no medication, and then a four-week course of levetiracetam (125 mg twice daily). The second group received these same treatments in the reverse order. This blinded, crossover approach ensured that neither the participants nor the researchers knew whether the active drug was being administered during any given week, thereby mitigating expectancy effects.
Measuring Cognitive Gains: A Multifaceted Approach
Throughout the study, participants underwent a battery of cognitive assessments designed to measure improvements in key areas affected by Alzheimer’s disease. These tests evaluated problem-solving abilities, reasoning skills, word recall, and spatial navigation. A particularly innovative assessment involved a driving simulator, where participants were tasked with navigating a virtual city, requiring them to learn and remember routes and react to simulated traffic scenarios. This immersive approach provided a practical and engaging measure of cognitive function in a real-world context.
Clear Benefits for a Specific Alzheimer’s Subtype
The findings indicated that while patients treated with levetiracetam showed general trends toward cognitive improvement, the most significant and "clear benefit" was observed in the subgroup of patients who had been identified with silent epileptic activity. This highlighted the drug’s targeted efficacy for this specific subtype of Alzheimer’s.
"There were very clear differences between the groups," Dr. Vossel stated. "There’s a subtype of Alzheimer’s disease, consider it an epileptic variant, that’s quite common, occurring in approximately 60% of patients. Patients with this form of Alzheimer’s disease show symptomatic improvement with levetiracetam."
This revelation suggests that a substantial portion of individuals diagnosed with Alzheimer’s disease may be experiencing a form of the condition that is particularly responsive to anti-seizure medication.
Shifting Diagnostic and Treatment Paradigms
Currently, routine diagnostic protocols for Alzheimer’s disease do not typically include screening for silent seizures. The study’s findings strongly advocate for a reevaluation of this approach. The research team suggests that clinicians should consider the possibility of epileptic activity in their Alzheimer’s patients, particularly those presenting with certain clinical indicators.
"There are some clinical features that indicate Alzheimer’s patients are more likely to be having silent epileptic activity," Dr. Vossel noted. "The main one is being under the age of 65 when symptoms begin." This observation is particularly noteworthy, as the study also indicated that younger patients appeared to benefit from levetiracetam even in the absence of detectable epileptic activity, hinting at broader mechanisms of action or an increased susceptibility in this demographic.
A Complementary Approach to Existing Therapies
It is important to note that participants in this study were already receiving standard, FDA-approved medications for Alzheimer’s disease. The addition of levetiracetam demonstrated an improvement in cognitive function that surpassed the benefits derived from existing treatments alone. This suggests that levetiracetam could serve as a valuable add-on therapy, enhancing the overall management of cognitive symptoms.
Future Directions: Long-Term Efficacy and Broader Applications
While the current study focused on short-term cognitive improvements, the research team acknowledges the critical need to investigate the long-term effects of levetiracetam. Ongoing studies are underway to determine whether sustained treatment with the drug can potentially slow the progression of Alzheimer’s disease itself.
"This study was intended to look for cognitive improvement during a short course of treatment," Dr. Vossel clarified. "There are other studies that are ongoing to see if the drug can help slow the disease course over longer periods."
Looking ahead, UCLA researchers plan to expand their efforts by recruiting a more diverse patient population to ensure the findings are generalizable across different demographic groups. Furthermore, they intend to explore the efficacy of other anti-seizure medications, which could broaden the therapeutic arsenal for Alzheimer’s patients with this specific neurological comorbidity.
A Timeline of Discovery and Support
The research that culminated in this significant publication has been a long-term endeavor. Dr. Vossel initiated the study in 2014 while he was affiliated with the University of California, San Francisco (UCSF). Patient enrollment took place at both UCSF and the University of Minnesota, underscoring the collaborative nature of this extensive research project. The study received vital financial support from prestigious organizations such as the Alzheimer’s Association, the National Institutes of Health (NIH), and various private gift funds, highlighting the widespread recognition of the importance of this line of inquiry.
Broader Implications for Neurological Health
The implications of this research extend beyond the immediate impact on Alzheimer’s patients. The identification of silent epileptic activity as a significant contributor to cognitive decline in AD could prompt a paradigm shift in how neurological disorders are understood and treated. It underscores the complex interplay between different neurological conditions and the potential for unexpected therapeutic benefits when medications are repurposed or investigated in new contexts.
For families and caregivers of individuals with Alzheimer’s, this study offers a beacon of hope. The prospect of an inexpensive, readily available medication that can measurably improve cognitive function for a substantial subset of patients provides a tangible benefit that can enhance quality of life and potentially alleviate some of the burdens associated with the disease. The development of more targeted diagnostic tools to identify this "epileptic variant" of Alzheimer’s will be a crucial next step in translating these promising findings into widespread clinical practice. The future of Alzheimer’s treatment may well involve a more nuanced approach, recognizing and addressing the diverse underlying mechanisms that contribute to this devastating disease.